<DOC>
	<DOC>NCT02259803</DOC>
	<brief_summary>Study to investigate the relative bioavailability of fixed-dose combination tablet vs. mono-components of telmisartan and amlodipine</brief_summary>
	<brief_title>Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1. Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12lead ECG, clinical laboratory tests, no finding of clinical relevance, no evidence of a clinically relevant concomitant disease 2. Age ≥20 and Age ≤35 years 3. Body weight ≥50 kg 4. BMI ≥17.6 and BMI ≤26.4 kg/m2 (Body Mass Index) 5. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice 1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 3. Chronic or relevant acute infections 4. Any clinical relevant findings of the laboratory test deviating from normal 5. Positive result for hepatitis B antigen, anti hepatitis C virus anti bodies, syphilitic test or HIV test 6. Surgery of gastrointestinal tract (except appendectomy) 7. History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts 8. History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis) 9. History of serious renal dysfunction 10. History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney 11. History of cerebrovascular disorder 12. History of hyperkalemia 13. Known hypersensitivity to any component of the formulation, or to any other angiotensin II receptor blockers, angiotensin converting enzyme or dihydropyridine 14. Intake of drugs with a long halflife (≥24 hours) within at least one month or less than 10 halflives of the respective drug prior to administration or during the trial 15. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial 16. Participation in another trial with an investigational drug within 4 months or 6 halflives of the investigational drug prior to administration 17. Smoker (≥20 cigarettes/day) 18. Alcohol abuse (60 g or more ethanol/day: ex. 3 middlesized bottles of beer, 3 gous (equivalent to 540 mL) of sake) 19. Drug abuse 20. Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial) 21. Excessive physical activities (within 1 week prior to administration or during the trial) 22. Intake of alcohol within 2 days prior to administration 23. Inability to comply with dietary regimen of study centre 24. Intake of any drugs/supplements with ingredient of hypericum perforatum or citrus fruits (e.g. grapefruits, Sevilla orange) within 5 days prior to administration 25. Inability to refrain from smoking on trial days 26. Any other volunteers whom, the principal investigator or sub investigator would not allow to participate in this study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>